These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12446422)

  • 41. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.
    Greenberg PL
    J Natl Compr Canc Netw; 2013 Jul; 11(7):877-84; quiz 885. PubMed ID: 23847221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular and genetic features of myelodysplastic syndromes.
    Greenberg PL
    Int J Lab Hematol; 2012 Jun; 34(3):215-22. PubMed ID: 22212119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors.
    Vandermolen L; Rice L; Rose MA; Lynch EC
    Arch Intern Med; 1988 Mar; 148(3):653-6. PubMed ID: 3341866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile.
    Ma L; Ceuppens J; Kasran A; Delforge M; Boogaerts M; Vandenberghe P
    Leuk Res; 2007 Oct; 31(10):1373-82. PubMed ID: 17188353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The current perspective of low-grade myelodysplastic syndrome in children.
    Hasegawa D
    Int J Hematol; 2016 Apr; 103(4):360-4. PubMed ID: 26939774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nucleolar abnormalities--a defect of the nucleolar preribosome assembly--in ringed sideroblasts in refractory anaemia with ringed sideroblasts (RARS) of myelodysplastic syndrome (MDS). An electron microscopic study.
    Smetana K; Cermák J; Jirásková I; Malasková V
    Sb Lek; 2003; 104(2):199-207. PubMed ID: 14577129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in supportive care of myelodysplastic syndromes.
    Gordon MS
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):21-4. PubMed ID: 10530713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluating the prognosis of patients with myelodysplastic syndromes.
    Aul C; Giagounidis A; Germing U; Ganser A
    Ann Hematol; 2002 Sep; 81(9):485-97. PubMed ID: 12373348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
    Ziarkiewicz M; Dwilewicz-Trojaczek J; Pastwińska A; Chmarzyńska E; Paszkowska-Kowalewska M; Koperski Ł; Jędrzejczak WW; Ziarkiewicz-Wróblewska B
    Pol J Pathol; 2010; 61(2):105-9. PubMed ID: 20924996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
    Ghaddar HM; Stass SA; Pierce S; Estey EH
    Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Strategies for achieving transfusion independence in myelodysplastic syndromes.
    Thomas ML
    Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Relationship between mitochondrial DNA and myelodysplastic syndromes - review].
    Zhang QQ; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):712-6. PubMed ID: 18549660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Auto- and alloreactivity of T lymphocytes in myelodysplastic syndrome].
    Cukrová V; Neuwirtová R; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
    Cas Lek Cesk; 2006; 145(8):647-52; discussion 653. PubMed ID: 16995421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Achievements in Understanding and Treatment of Myelodysplastic Syndromes.
    Hellström-Lindberg E; Willman C; Barrett AJ; Saunthararajah Y
    Hematology Am Soc Hematol Educ Program; 2000; ():110-132. PubMed ID: 11701538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.
    Kern W; Bacher U; Schnittger S; Alpermann T; Haferlach C; Haferlach T
    Cytometry B Clin Cytom; 2013 May; 84(3):194-7. PubMed ID: 23283847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues.
    Besa EC
    Med Clin North Am; 1992 May; 76(3):599-617. PubMed ID: 1578959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.